… momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via new research partnership … on RNA editing, ProQR made important progress with Axiomer, our ADAR-mediated RNA editing technology platform,” …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its … ProQR and further supports the confidence we have in our Axiomer technology,” said Daniel A. de Boer, Founder and CEO … with meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides. Key data reported …
… directed toward high conviction targets utilizing ProQR’s Axiomer technology INDIANAPOLIS; LEIDEN, Netherlands; and … announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its … at the RNA Editing Summit in Boston, highlighting its Axiomer technology platform and AX-0810, the Company’s … with meaningful changes in biomarkers in NHPs using Axiomer RNA Editing Oligonucleotides. At ASGCT, ProQR and …
… Our leading intellectual property portfolio protects our Axiomer ® ADAR-mediated RNA editing platform technology and … patent protection related to its RNA editing platform, Axiomer ® , including more than 11 published patent families, … its IP estate around ADAR-mediated RNA editing. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its … pleased with the continued progress in advancing our Axiomer ® RNA editing platform and believe we’re only at the … In November ProQR announced its IP estate surrounding its Axiomer ® RNA editing platform was further strengthened by: …
